====================
QUESTION:
{
  "CASE_CORE": {
    "VISIT_DATE": "2024-10-29",
    "last_platinum_end_date": "2024-10-23",
    "first_relapse_date": "Unknown",
    "PFI_days": "Unknown",
    "PLATINUM_STATUS": "Unknown",
    "PLATINUM_STATUS_CURRENT": "Unknown",
    "PLATINUM_PFI_CURRENT": "Unknown",
    "SCENE": "Frontline_PDS_or_NACT_IDS",
    "PLATINUM_HISTORY": [
      {
        "line": "1L",
        "start_date": "2024-08-23",
        "end_date": "2024-10-23",
        "first_relapse_date": "Unknown",
        "PFI_days": "Unknown",
        "status": "Unknown",
        "evidence_type": "Clinical",
        "evidence": "BEP方案化疗2程:BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3，q21d，末次2024.10.23"
      }
    ],
    "DIAGNOSIS": {
      "primary": "Ovarian mixed germ cell tumor",
      "histology": "无性细胞瘤合并畸胎瘤成分",
      "site": "Ovary",
      "laterality": "Right",
      "components": [
        "畸胎瘤成分"
      ]
    },
    "STAGE": {
      "stage_text": "Unknown",
      "stage_system": "Unknown",
      "stage_basis": "Unknown"
    },
    "INITIAL_TREATMENT": "Yes",
    "SURGERY_DONE": {
      "performed": "Yes",
      "date": "2024-09-02",
      "procedure": "Laparoscopic right ovary + salpingectomy"
    },
    "NEOADJUVANT": "Yes",
    "ADJUVANT_TREATMENT": {
      "given": "Unknown",
      "regimens": [
        "BEP方案化疗2程:BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3，q21d"
      ],
      "cycles_or_courses": "2 cycles"
    },
    "LINE_OF_THERAPY": [
      {
        "line": "1L",
        "intent": "Unknown",
        "regimen": "BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3, q21d",
        "start_date": "2024-08-23",
        "end_date": "2024-10-23",
        "cycles": "2"
      }
    ],
    "MAINTENANCE": "Unknown",
    "MAINTENANCE_DETAIL": {
      "given": "Unknown",
      "regimens": [],
      "start_date": "Unknown",
      "end_date": "Unknown"
    },
    "RELAPSE": "Unknown",
    "RELAPSE_DATE": {
      "date": "Unknown",
      "type": "Unknown",
      "evidence": ""
    },
    "HRD": "Unknown",
    "BRCA1": "Unknown",
    "BRCA2": "Unknown",
    "BIOMARKERS": {
      "TMB": "Unknown",
      "MSI": "Unknown",
      "PDL1_CPS": "Unknown",
      "HER2": "Unknown",
      "AFP": "<2 (2024-10-22)",
      "CA125": "36.10 (2024-09-27)"
    },
    "CURRENT_STATUS": "Post right oophorectomy; received 2 cycles BEP; left ovarian surface nodule noted, under imaging evaluation",
    "TIMELINE": {
      "events": [
        {
          "date": "2024-08-23",
          "event_type": "Chemo",
          "description": "Start BEP chemotherapy (2 cycles)",
          "regimen_or_test": "BEP方案化疗: BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3, q21d",
          "key_result": "AFP 15.84; CA125 44.1"
        },
        {
          "date": "2024-09-02",
          "event_type": "Surgery",
          "description": "Laparoscopic right ovary + salpingectomy",
          "regimen_or_test": "Pathology performed",
          "key_result": "Pathology: 卵巢恶性肿瘤, 无性细胞瘤合并畸胎瘤成分"
        },
        {
          "date": "2024-09-27",
          "event_type": "Imaging",
          "description": "MRI: post-right oophorectomy, left adnexal/posterior to left ovary mass; small pelvic effusion",
          "regimen_or_test": "MRI pelvis",
          "key_result": "Left ovarian extra-surface mass noted"
        },
        {
          "date": "2024-09-28",
          "event_type": "Imaging",
          "description": "CT pelvis post-op showing pelvic mass",
          "regimen_or_test": "CT",
          "key_result": "Postoperative pelvic mass"
        },
        {
          "date": "2024-09",
          "event_type": "Other",
          "description": "亮丙瑞林 1 time (subcutaneous injection)",
          "regimen_or_test": "亮丙瑞林",
          "key_result": ""
        },
        {
          "date": "2024-10-22",
          "event_type": "Lab",
          "description": "AFP measurement",
          "regimen_or_test": "AFP",
          "key_result": "AFP <2"
        },
        {
          "date": "2024-10-23",
          "event_type": "Chemo",
          "description": "Last BEP administration (documented last dose)",
          "regimen_or_test": "BEP",
          "key_result": "Last administration 2024-10-23"
        }
      ],
      "constraints": {
        "min_events": 3,
        "max_events": 30,
        "must_include": [
          "first diagnostic imaging or pathology confirmation (if available)"
        ],
        "ordering_rules": {
          "prioritize_last_event": true
        }
      }
    }
  },
  "TIMELINE": {
    "events": [
      {
        "date": "2024-08-23",
        "event_type": "Chemo",
        "description": "Start BEP chemotherapy (2 cycles)",
        "regimen_or_test": "BEP方案化疗: BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3, q21d",
        "key_result": "AFP 15.84; CA125 44.1"
      },
      {
        "date": "2024-09-02",
        "event_type": "Surgery",
        "description": "Laparoscopic right ovary + salpingectomy",
        "regimen_or_test": "Pathology performed",
        "key_result": "Pathology: 卵巢恶性肿瘤, 无性细胞瘤合并畸胎瘤成分"
      },
      {
        "date": "2024-09-27",
        "event_type": "Imaging",
        "description": "MRI: post-right oophorectomy, left adnexal/posterior to left ovary mass; small pelvic effusion",
        "regimen_or_test": "MRI pelvis",
        "key_result": "Left ovarian extra-surface mass noted"
      },
      {
        "date": "2024-09-28",
        "event_type": "Imaging",
        "description": "CT pelvis post-op showing pelvic mass",
        "regimen_or_test": "CT",
        "key_result": "Postoperative pelvic mass"
      },
      {
        "date": "2024-09",
        "event_type": "Other",
        "description": "亮丙瑞林 1 time (subcutaneous injection)",
        "regimen_or_test": "亮丙瑞林",
        "key_result": ""
      },
      {
        "date": "2024-10-22",
        "event_type": "Lab",
        "description": "AFP measurement",
        "regimen_or_test": "AFP",
        "key_result": "AFP <2"
      },
      {
        "date": "2024-10-23",
        "event_type": "Chemo",
        "description": "Last BEP administration (documented last dose)",
        "regimen_or_test": "BEP",
        "key_result": "Last administration 2024-10-23"
      }
    ],
    "constraints": {
      "min_events": 3,
      "max_events": 30,
      "must_include": [
        "first diagnostic imaging or pathology confirmation (if available)"
      ],
      "ordering_rules": {
        "prioritize_last_event": true
      }
    }
  },
  "MED_ONC": {
    "current_regimen": {
      "name": "Unknown",
      "last_admin_date": "2024-10-23",
      "cycle_info": "2 cycles completed"
    },
    "planned_next_regimen": "Unknown",
    "prior_systemic_therapies": [
      "BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3, q21d"
    ],
    "genetic_testing": {
      "somatic": [],
      "germline": []
    },
    "monitoring_points": []
  },
  "RADIOLOGY": {
    "studies": [
      {
        "date": "2024-09-27",
        "modality": "MRI",
        "anatomic_sites": [
          "Left ovary",
          "Pelvis"
        ],
        "findings": [
          "Post-right oophorectomy; left adnexal/posterior to left ovary mass",
          "Small pelvic effusion"
        ],
        "impression": "Left-sided adnexal extra-surface mass; consider implantation",
        "trend_vs_prior": "Unknown"
      },
      {
        "date": "2024-09-28",
        "modality": "CT",
        "anatomic_sites": [
          "Pelvis"
        ],
        "findings": [
          "Postoperative pelvic mass"
        ],
        "impression": "Pelvic postoperative change with residual mass",
        "trend_vs_prior": "Unknown"
      },
      {
        "date": "Unknown",
        "modality": "MRI",
        "anatomic_sites": [
          "Left ovary"
        ],
        "findings": [
          "Left ovarian surface solid nodule 1.8cm, decreased in size compared with prior"
        ],
        "impression": "Left ovarian surface solid nodule 1.8cm; decreased; suspect implantation; recommend FAPI",
        "trend_vs_prior": "Improved"
      }
    ],
    "next_imaging_plan": {
      "modality": "FAPI",
      "timing": "Unknown"
    }
  },
  "PATHOLOGY": {
    "specimens": [
      {
        "date": "2024-09-02",
        "site": "Right adnexa",
        "diagnosis": "卵巢恶性肿瘤，结合免疫组化诊断为：无性细胞瘤合并畸胎瘤成分（占比约10%），伴局部坏死及血管增生。病理会诊：卵巢混合性生殖细胞肿瘤，以无性细胞瘤成分为主，合并少量成熟性畸胎瘤成分；输卵管慢性炎。",
        "components": [
          "无性细胞瘤成分",
          "畸胎瘤成分"
        ],
        "grade": "Unknown",
        "tumor_size": "Unknown",
        "laterality": "Right",
        "sample_type": "Resection",
        "involvement_sites": [],
        "ihc": [
          {
            "marker": "SALL4",
            "result": "(+)"
          },
          {
            "marker": "Oct4",
            "result": "(+)"
          },
          {
            "marker": "PLAP",
            "result": "(+)"
          },
          {
            "marker": "D2-40",
            "result": "(+)"
          },
          {
            "marker": "GPC-3",
            "result": "(-)"
          },
          {
            "marker": "AFP",
            "result": "(-)"
          },
          {
            "marker": "ZBTB16",
            "result": "(-)"
          },
          {
            "marker": "EMA",
            "result": "(-)"
          },
          {
            "marker": "CD30",
            "result": "(-)"
          },
          {
            "marker": "CD117",
            "result": "(+)"
          },
          {
            "marker": "Ki-67",
            "result": "(+约80％)"
          }
        ],
        "molecular": [],
        "raw_text": "术后病理：卵巢恶性肿瘤，结合免疫组化诊断为：无性细胞瘤合并畸胎瘤成分（占比约10%），伴局部坏死及血管增生。病理会诊（右附件）：卵巢混合性生殖细胞肿瘤，以无性细胞瘤成分为主，合并少量成熟性畸胎瘤成分；输卵管慢性炎。免疫组化：SALL4（+），Oct4（+），PLAP（+），D2-40（+），GPC-3（-），AFP（-），ZBTB16（-），EMA（-），CD30（-），CD117（+），Ki-67（+约80％）",
        "uncertainty_or_missing": [
          "Stage not provided"
        ]
      }
    ]
  },
  "NUC_MED": {
    "studies": []
  },
  "LAB_TRENDS": {
    "labs": [
      {
        "analyte": "AFP",
        "unit": "ng/mL",
        "reference_range": "Unknown",
        "latest": {
          "date": "2024-10-22",
          "value": "<2",
          "flag": "↓"
        },
        "history": [
          {
            "date": "2024-08-23",
            "value": "15.84",
            "flag": "Unknown"
          },
          {
            "date": "2024-10-22",
            "value": "<2",
            "flag": "↓"
          }
        ]
      },
      {
        "analyte": "CA125",
        "unit": "U/ml",
        "reference_range": "Unknown",
        "latest": {
          "date": "2024-09-27",
          "value": "36.10",
          "flag": "↑"
        },
        "history": [
          {
            "date": "2024-08-23",
            "value": "44.1",
            "flag": "Unknown"
          },
          {
            "date": "2024-09-27",
            "value": "36.10",
            "flag": "↑"
          }
        ]
      },
      {
        "analyte": "NSE",
        "unit": "ng/ml",
        "reference_range": "Unknown",
        "latest": {
          "date": "2024-09-27",
          "value": "19.60",
          "flag": "↑"
        },
        "history": [
          {
            "date": "2024-09-27",
            "value": "19.60",
            "flag": "↑"
          }
        ]
      }
    ],
    "milestones": [
      {
        "date": "2024-08-23",
        "type": "ChemoStart",
        "description": "Start BEP chemotherapy"
      },
      {
        "date": "2024-09-02",
        "type": "Surgery",
        "description": "Laparoscopic right ovary + salpingectomy"
      },
      {
        "date": "2024-10-23",
        "type": "ChemoEnd",
        "description": "Last documented BEP administration"
      },
      {
        "date": "2024-09-27",
        "type": "Imaging",
        "description": "MRI showing left ovarian mass"
      }
    ]
  }
}

RESPONSE:
Final Assessment:
Mixed ovarian germ cell tumour (dysgerminoma‑predominant) post right adnexectomy and 2 BEP cycles, with a shrinking but indeterminate 1.8 cm left ovarian surface nodule and incomplete staging, organ-function, and fertility information.

Core Treatment Strategy:
- Do not modify systemic‑therapy plan or schedule further cycles until FIGO stage, staging completeness, and organ function are clarified.
- Arrange unified post‑BEP restaging: contrast CT/MRI abdomen–pelvis ± chest plus whole‑body PET/FAPI to assess left nodule and extrapelvic disease.
- Request pathology addendum to provide full staging details (tumour size, capsule/surface, washings, extraovarian disease, FIGO stage, teratoma maturity).
- Implement standardized serial tumour markers (AFP, β‑hCG, LDH, CA125, NSE) and document renal, pulmonary, marrow status and fertility goals to guide chemo vs fertility‑sparing surgery.

Change Triggers:
- If imaging/PET shows active left implant or additional disease, prioritize completion/optimization of systemic therapy and consider non‑fertility‑sparing surgery.
- If imaging/PET shows no active disease and markers normalize, consider limited fertility‑sparing surgery or surveillance rather than intensifying chemotherapy.
- If organ‑function assessment reveals significant BEP toxicity, de‑escalate or switch systemic approach and increase reliance on surgical/local control.

